Vanda Pharmaceuticals | VNDA - Operating Expenses

Stock Price
7.44
Daily Change
0.02 0.27%
Monthly
0.40%
Yearly
56.63%
Q1 Forecast
4.24

Vanda Pharmaceuticals reported $466M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Agios Pharmaceuticals USD 129.75M 9.76M Sep/2025
Akebia Therapeutics USD 43.82M 16.98M Mar/2025
Alnylam Pharmaceuticals USD 881.04M 91.16M Sep/2025
Anika Therapeutics USD 146.8M 867K Sep/2025
Arrowhead Research USD 223.22M 10.86M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
Halozyme Therapeutics USD 136.34M 13.06M Sep/2025
Heron Therapeutics USD 38.47M 4M Sep/2024
Insmed USD 403.69M 42.4M Sep/2025
J&J USD 18.97B 2.38B Dec/2025
Lexicon Pharmaceuticals USD 57M 10.54M Jun/2024
Ligand Pharmaceuticals USD 8.29M 32.17M Sep/2025
Merck USD 10.16B 558M Dec/2025
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Moderna USD 1.28B 232M Sep/2025
Novartis USD 9.77B 401M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
PTC Therapeutics USD 207.52M 6.21M Sep/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 10.51B 1.21B Dec/2025
Takeda JPY 1.02T 400.98B Dec/2025
Teva Pharmaceutical Industries USD 4.22B 812M Dec/2025
Ultragenyx Pharmaceutical USD 330.82M 56.44M Sep/2025
Vanda Pharmaceuticals USD 466M 20.33M Sep/2025
Veracyte USD 108.76M 7.09M Sep/2025